Friday, July 10, 2026

biotech · Major Depressive Disorder · Schizophrenia · NBIX

NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal

6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
Status
Public
HQ
6027 Edgewood Bend Ct, San Diego, California 92130, US
Founded
1992
Employees
2,307
Programs
79
Drugs
28
Patents
111
Clinical program

Effect of NBI-921355 on corticospinal excitability in healthy participants

Phase 1 · other · Epilepsy

Effect of NBI-921355 on corticospinal excitability in healthy participants for Epilepsy is a Phase 1 program (other) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Internal code NBI-921355-1785

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
NEUROCRINE BIOSCIENCES INC
Phase
Phase 1
Modality
other
Indication
Epilepsy
Status
active
Trials
1